In August 2021, QuaCell Biotechnology, Co., Ltd. ("QuaCell") announced that it has completed its B-round of financing of nearly 200 million yuan. This round of financing is led by Longwater Investment, China Science and Technology Innovation, Huangpu Pharmaceutical Fund, and followed by existing shareholders.
Quacell is a rapidly developing global biotechnology company headquartered in Zhongshan City in Guangdong-Hong Kong-Macao Greater Bay Area. Adhering to the requirements of ISO and GMP regulations, QuaCell focuses on the research and manufacturing of cell culture medium and provides key raw materials for global biopharmaceutical and gene therapy enterprises; Quacell focuses on customer requirements, provides integrated services from DNA to GMP production in line with FDA/NMPA requirements, and wins the recognition and trust of nearly 100 biopharmaceutical and biotechnology enterprise customers at home and abroad.
Longwater Investment focuses on the key materials and technologies that can drive industrial development. The products and technologies of enterprises invested by Longwater Investment are widely used in new energy, electronics, semiconductors, sustainable development, life sciences and other industrial and consumption upgrading fields.
Llinks is on behalf of Longwater Investment in dealing with legal due diligence report, transaction structure designing, transaction documents drafting and negotiation.
